NCT01046916

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Millennium Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter phase 2 open-label single-arm study that will evaluate the safety and efficacy of TAK-700 in patients with castration-resistant prostate cancer (CRPC) without radiographic evidence of metastases who have a rising prostate-specific antigen (PSA).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	TAK-700	TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule

Timeline

• Start date: 2010-05-01
• Primary completion: 2013-01-01
• Completion: 2013-03-01
• First posted: 2010-01-12
• Last updated: 2016-04-04

Locations

3 sites across 1 country: United States